Review the latest information on the efficacy and safety of fixed-dose LAMA/LABA combinations in treatment of patients with COPD, as presented at a recent meeting in San Francisco. Ask our experts your questions related to COPD and find answers to questions from the meeting.


Long-acting bronchodilators are the cornerstone of maintenance therapy for patients with chronic obstructive pulmonary disease (COPD). A variety of long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABAs) are available for the management of COPD. An increasing number of fixed-dose LAMA/LABA combinations have been developed and approved; these combinations have the potential to provide synergistic effects through different mechanisms of action, maximize bronchodilation, and simplify COPD treatment regimens. Authored by Richard Casaburi, MD, Gary Ferguson, MD, and David Mannino, MD, this supplement provides a review of the safety and efficacy of current and emerging inhaled fixed-dose LAMA/LABA combinations for patients with COPD.


FAQ is an opportunity for you to have your COPD clinical questions addressed by expert faculty. Your questions will be answered by email within 2 weeks.


Does the FLAME data put indacaterol/glycopyrrolate as a superior LABA/LAMA in the ex US scenario based on existing evidence to date?

2016 ATS COPD: Fixed Dose LAMA/LABA Inhalers in COPD: What the Trials Tell Us

These slides are from a recent symposium held in San Francisco on May 17, 2016. Through an interactive, case-based format, Dr. Richard Casaburi, Dr. Gary Ferguson, and Dr. David Mannino present an overview of the efficacy and safety of current and emerging fixed dose LAMA/LABA combination inhalers for patients with COPD.

Click here to download the COPD Foundation's provider and patient resource sheet

Download [pptx » 3MB]

Access other Therapeutic Areas: